Interaction Checker

Wechselwirkungen von Ruxolitinib

Ruxolitinib (Jakafi, Opzelura), ein JAK-Inhibitor, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 75 dokumentierte Wechselwirkungen: 10 schwerwiegende, 65 mittelschwere, 0 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (10)

  • AbataceptImmunsuppressivumSchwerwiegend

    Additionally, concomitant use of ORENCIA with other biologic RA/PsA therapy or JAK inhibitors is not recommended. (Fachinformation zu Abatacept, Warnhinweise und Vorsichtsmaßnahmen)

  • AbrocitinibJAK-InhibitorSchwerwiegend

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Fachinformation zu Ruxolitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • AdalimumabImmunsuppressivumSchwerwiegend

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Fachinformation zu Ruxolitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • BaricitinibJAK-InhibitorSchwerwiegend

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Fachinformation zu Ruxolitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • EtanerceptImmunsuppressivumSchwerwiegend

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Fachinformation zu Ruxolitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • FluconazolAzol-AntimykotikumSchwerwiegend

    Fluconazole: Avoid concomitant use with fluconazole doses greater than 200 mg. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • InfliximabImmunsuppressivumSchwerwiegend

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Fachinformation zu Ruxolitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • RitlecitinibJAK-InhibitorSchwerwiegend

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Fachinformation zu Ruxolitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • TofacitinibImmunsuppressivumSchwerwiegend

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Fachinformation zu Ruxolitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • UpadacitinibImmunsuppressivumSchwerwiegend

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Fachinformation zu Ruxolitinib, Warnhinweise und Vorsichtsmaßnahmen)

Mittelschwere Wechselwirkungen (65)

  • AmiodaronAntiarrhythmikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • AprepitantCYP3A4-HemmerMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • ArmodafinilZNS-StimulansMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Atazanavirantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • BosentanCYP3A4-InduktorMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • CarbamazepinAntiepileptikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • CenobamatAntiepileptikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • CiclosporinImmunsuppressivumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • CimetidinH2-BlockerMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • ClarithromycinMakrolid-AntibiotikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • ClobazamBenzodiazepinMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Darunavirantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Darunavir und Cobicistatantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • DeferasiroxEisenpräparatMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • DexamethasonKortikosteroidMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • DiltiazemCalciumkanalblockerMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • DronedaronAntiarrhythmikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Efavirenzantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Efavirenz, Lamivudin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Elvitegravir, Cobicistat, Emtricitabin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • ErythromycinMakrolid-AntibiotikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • EslicarbazepinAntiepileptikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Etravirinantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • EverolimusImmunsuppressivumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Fosamprenavirantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • FosaprepitantCYP3A4-HemmerMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • FosphenytoinAntiepileptikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • GriseofulvinAntimykotikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • ImatinibCYP3A4-HemmerMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • IsoniazidAntibiotikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • ItraconazolAzol-AntimykotikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • IvacaftorCYP3A4-HemmerMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • KetoconazolAzol-AntimykotikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Lenacapavirantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Lopinavir und Ritonavirantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • LorlatinibCYP3A4-InduktorMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • MifepristonCYP3A4-HemmerMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • MirabegronBeta-Adrenozeptor-AgonistMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • MitapivatCYP3A4-InduktorMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • MitotanCYP3A4-InduktorMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • ModafinilZNS-StimulansMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • NafcillinPenicillin-AntibiotikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • NefazodonAntidepressivumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Nevirapinantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Nirmatrelvir und RitonavirVirostatikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • OxcarbazepinAntiepileptikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • PalbociclibCYP3A4-HemmerMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • PerampanelAntiepileptikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • PhenobarbitalBarbituratMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Phentermin und TopiramatZNS-StimulansMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • PhenytoinAntiepileptikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • PosaconazolAzol-AntimykotikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • PrimidonAntiepileptikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • RanolazinQT-verlängerndes ArzneimittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • RifabutinAntibiotikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • RifampicinAntibiotikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • RifapentinAntibiotikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Ritonavirantiretrovirales ArzneimittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • SuvorexantSchlaf- und BeruhigungsmittelMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • SuzetriginCYP3A4-InduktorMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • Tabak und RauchenTabak und CannabisMittelschwer

    Secondary Malignancies: Monitor for development of secondary malignancies, particularly in patients who are current or past smokers. (Fachinformation zu Ruxolitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • TicagrelorThrombozytenaggregationshemmerMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • TopiramatAntiepileptikumMittelschwer

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • VerapamilCalciumkanalblockerMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

  • VoriconazolAzol-AntimykotikumMittelschwer

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Fachinformation zu Ruxolitinib, Arzneimittelwechselwirkungen)

Prüfen Sie Ruxolitinib gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.